CVS Health to reinstate Zepbound coverage, add new weight-loss pill Foundayo to drug plans
By
, USA TODAY
3d ago· 4 min readenNews
85/100
Golden Brown
Bagelometer↗
Pulled from the oven just right. Trustworthy, fact-dense, deeply satisfying.
Score85TypenewsSentimentpositive
Summary
CVS Health, through its pharmacy benefit manager CVS Caremark, will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound starting October 1 and begin coverage of the new anti-obesity pill Foundayo starting June 1 for millions of Americans on private insurance plans. This move comes a year after CVS Caremark made Novo Nordisk's Wegovy a preferred GLP-1 medication, and signals expanding access to weight-loss drugs amid growing demand and competition in the obesity treatment market.
Key quotes
· 3 pulledCVS Health announced it will reinstate coverage of Eli Lilly's blockbuster weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo for millions of Americans on private insurance plans.
Coverage of Zepbound will begin Oct. 1 and coverage of Lilly's weight-loss pill Foundayo will start June 1.
The coverage will be on the standard template from CVS Caremark, a prescription drug manager used by insurers and employers for millions of Americans.
CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.
